The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 40 results
Sort by date: Descending
Encores: Not included
SLEEP (Annual Meeting of the Associated Professional Sleep Societies)
June 7th – 11th 2025
Sleep-wake disorders
POSTER
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients With Narcolepsy and Idiopathic Hypersomnia
AUTHOR(S)

Meera Modi,1 Brendon Yee,2 Julia Chapman,2 Angela D’Rozario,2 Roman Rosipal,3 Leonardo Jose Trejo,3 G.S.F. Ruigt,3 Ron Grunstein,2 Bhaskar Rege,1 Daniel G. Smith1

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy or Idiopathic Hypersomnia: A Phase 1b Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Derek Matthies,2 Shifang Liu,2 Sergey Yagoda,2 Bhaskar Rege2

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
POSTER
Evaluation of the Novel Orexin 2 Receptor Agonist ALKS 2680 on Measures of Arousal Circuit Activation in Rodents
AUTHOR(S)

Julie M. Brooks,1 Angelica M. Patino,1 Corey B. Puryear,1 Laura A. Tan,1 Brian Raymer1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
PRESENTATION
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients with Narcolepsy and Idiopathic Hypersomnia
AUTHOR(S)

Presented by Julia Chapman

View presentation
Sleep-wake disorders
Sleep-wake disorders
PRESENTATION
Investigational Orexin-2 Receptor Agonists for Narcolepsy Types 1 and 2, Idiopathic Hypersomnia, and Beyond
AUTHOR(S)

Presented by Marcus Yountz

View presentation
Sleep-wake disorders
American Society of Clinical Psychopharmacology
May 27th – 30th 2025
Bipolar Disorder
Schizophrenia
POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia